Impact of the SARS-CoV-2 Pandemic in Candidaemia, Invasive Aspergillosis and Antifungal Consumption in a Tertiary Hospital.
Juan Vicente Mulet BayonaNuria Tormo PalopCarme Salvador-GarcíaBegoña Fuster EscriváMercedes Chanzá AviñóPilar Ortega GarcíaConcepción Gimeno CardonaPublished in: Journal of fungi (Basel, Switzerland) (2021)
In addition to the increase in fungal infections that has been observed in the last few decades, it has been reported that severe clinical COVID-19 can increase the risk of invasive fungal infections. The main objective of this study was to evaluate if there had been an increase in candidaemia and invasive pulmonary aspergillosis (IPA) cases since the onset of the SARS-CoV-2 pandemic. Data were retrospectively collected from April 2019 to March 2021, from patients admitted to Consorcio Hospital General Universitario de Valencia (Spain). A total of 152 candidaemia cases (56 of which were due to Candida auris) and 108 possible IPA cases were detected. A great increase in candidaemia cases was produced during the first and the third epidemic waves of the SARS-CoV-2 pandemic (June 2020, and January 2021, respectively), while an increase in IPA cases was produced during the third wave. The 28-day mortality rates in patients affected by candidaemia and IPA increased in 2020 and 2021. C. auris has displaced the other Candida species, becoming the most isolated Candida species in blood cultures since the onset of the SARS-CoV-2 pandemic. Antifungal consumption increased in 2020 when compared to 2019, especially echinocandins, voriconazole and isavuconazole.
Keyphrases
- sars cov
- candida albicans
- respiratory syndrome coronavirus
- coronavirus disease
- end stage renal disease
- healthcare
- biofilm formation
- type diabetes
- chronic kidney disease
- pulmonary hypertension
- cardiovascular events
- emergency department
- machine learning
- electronic health record
- big data
- early onset
- cardiovascular disease
- risk factors
- drug induced
- deep learning